Friday, March 13, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

How Confident Are You in RFK Jr.’s Health Leadership?

Survey: Public Confidence in RFK Jr.’s Leadership in Health Policy

Response scale for all items:
Strongly disagree · Disagree · Neither agree nor disagree · Agree · Strongly agree

RFK Jr.’s prior work as an environmental attorney is relevant and beneficial to health policy leadership roles.
I am confident in RFK Jr.’s overall ability to lead and oversee national health policy institutions.
RFK Jr.’s public criticisms of segments of the pharmaceutical industry align with my understanding of current policy and market challenges.
RFK Jr.’s past public statements questioning aspects of vaccine policy and safety oversight reduce my confidence in his health policy judgment.
RFK Jr.’s past public statements questioning aspects of vaccine policy and safety oversight do not reduce my confidence in his health policy judgment.
RFK Jr.’s communication style and public persona support effective collaboration with scientific and regulatory stakeholders
RFK Jr.’s communication style and public persona could make it harder to build consensus across health agencies and expert groups.
RFK Jr.’s disclosed history of substance use disorder does not affect my assessment of his present capacity for public leadership.
RFK Jr.’s disclosed history of substance use disorder raises concerns for me about suitability for senior public leadership roles.
RFK Jr.’s policy positions indicate a willingness to challenge existing regulatory and industry frameworks in ways that could improve public health outcomes.
RFK Jr.’s policy positions introduce a level of uncertainty that could increase risk in national health decision-making.
I have sufficient familiarity with RFK Jr.’s public statements and policy positions to make a confident judgment about his leadership suitability.
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!